ArticleCancer control : journal of the Moffitt Cancer Center
Is Site of Radiation Therapy Associated With Pathologic Complete Response in Patients With Locally Advanced Esophageal Cancer?
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter to the Editor: Comment on " Is Site of Radiation Therapy Associated With Pathologic Complete Response in Patients With Locally Advanced Esophageal Cancer?"Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionNeoadjuvant chemoradiation (CRT) is commonly used for esophageal cancer (EC), with pathologic complete response (pCR) linked to improved prognosis. pCR rates range from 25%-30% for adenocarcinoma to 50% for squamous cell carcinoma (SCC). High-volume centers (HVCs) often yield favorable outcomes across various cancers. This study examines whether CRT delivery at an HVC impacts pCR and ypN0 rates in EC patients undergoing esophagectomy.MethodsIn this retrospective cohort analysis, we identified patients with clinical stage T2+/N+ EC who received neoadjuvant CRT and esophagectomy from a prospectively maintained database (1996-2019). CRT was delivered at the HVC or a community center (CC), while all surgeries occurred at the HVC. Primary outcomes were pCR and ypN0.ResultsAmong 708 patients, median age was 65 years, with 83.6% male and 95.3% white. Most had adenocarcinoma (87.9%) in the distal esophagus or gastroesophageal junction. CRT was delivered at CCs in 64.8% and at HVC in 35.2%. Radiation dose was higher at the HVC (mean 5195 vs 4944 cGy,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.